homepage-top-section

Under the deal, Simulations Plus shareholders will receive $18.50 per share, representing a 26% premium to the 60-day volume-weighted average price as of 15 June 2026. The company’s

This approval is said to be the first in the UK for a needle-free adrenaline treatment for children aged four years and older, weighing between 15kg and less

This approval covers patients with ccRCC who are at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions. This marks the

The application covers patients with stage III colon cancer characterised by deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) or microsatellite instability-high (MSI-H). The FDA is anticipated to make

EMA has now begun reviewing its use in adults following a non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack (TIA). The validation confirms the application is complete

The programme will investigate the ways in which AI can enhance the evaluation of precision and safety, better forecast risks, and identify impacts that current methods might overlook.

The deal centres on enhancing targeted treatments for solid tumours driven by KRAS mutations, which are considered especially challenging to treat. The companies stated that the Firelink DAC

The decision follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Aqneursa is approved across the EU

This advance recognises preliminary data indicating that salanersen may show substantial improvement over existing therapies for SMA. The FDA’s decision follows data from a Phase Ib study on